One dose (0.5 ml) contains: Active ingredients: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in fertilized hen’s eggs from healthy chicken flocks, and inactivated with formaldehyde, of the following strains:
A/California/7/2009 (H1N1) - like strain
(A/California/7/2009, NYMC X-181) 15 micrograms HA*
A/Perth/16/2009 (H3N2) - like strain
(A/Victoria/210/2009, NYMC X-187) 15 micrograms HA*
B/Brisbane/60/2008 - like strain
(B/Brisbane/60/2008, NYMC BX-35) 15 micrograms HA*
Excipients:sodium chloride; potassium chloride; potassium dihydrogen phosphate; disodium phosphate dihydrate; magnesium chloride hexahydrate; calcium chloride dihydrate and water for injection. This vaccine complies with the WHO recommendations (northern hemisphere) and EU decision for the 2011/2012 season.
Pharmaceutical form and contents:Suspension for injection in pre-filled syringe of 0.5 ml in box of 1 or 10. The vaccine appears as a clear liquid.
Pharmacotherapeutic category:Influenza vaccine. ATC code: J07BB02
Prophylaxis of Influenza (flu), especially in those who run an increased risk of associated complications. The use of Araflu should be based on official recommendations.
Contraindications:Hypersensitivity to the active substances, to any of the excipients and to residues, e.g. eggs, chicken proteins, such as ovalbumin. The vaccine may contain residues of the following substances, e.g. kanamycin and neomycin sulphate, formaldehyde, cetyltrimethylammonium bromide (CTAB) and polysorbate 80. Immunisation shall be postponed in patients with febrile illness or acute infection.
Precautions for use:As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. Araflu should under no circumstances be administered intravascularly.
Important information about some of the ingredients of Araflu:Araflu does not contain more than 0.2 μg of ovalbumin per 0.5 ml dose and 0.1 μg of ovalbumin per 0.25 ml dose. 1 dose of Araflu (0.5 ml) contains less than 1 mmol (39 mg) potassium and less than 1 mmol (23 mg) sodium. This means that Araflu is essentially free from potassium and sodium. None of the ingredients of the vaccine can cause influenza (flu).
Araflu may be given at the same time as other vaccines. Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified. The immunological response may be diminished if the patient is undergoing immunosuppressant treatment. Following influenza vaccination, false positive results in serology tests using the ELISA method (blood test) to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed.
Special warnings:Antibody response in patients with endogenous (due to illness) or iatrogenic (due to medicine) immunosuppression (poor immune response) may be insufficient.
Pregnancy and lactation:The limited data from vaccinations in pregnant women do not indicate that adverse foetal and maternal outcomes were attributable to the vaccine. The use of this vaccine may be considered from the second trimester of pregnancy. For pregnant women with medical conditions that increase their risk of complications from influenza, administration of the vaccine is recommended, irrespective of their stage of pregnancy. Araflu may be used during lactation.
Effects on ability to drive and use machines:Araflu is unlikely to produce an effect on the ability to drive and use machines.
Dosage, method and time of administration
- Adults and children over 36 months of age: 0.5 ml
- Children from 6 to 35 months of age: clinical data are limited.
Dosages of 0.25 ml or 0.5 ml have been used.
For children who have not been previously vaccinated, a second dose should be given after an interval of at least 4 weeks. If half a dose (0.25 ml) is to be administered, discard half the contained volume (up to the mark indicated on the syringe barrel), before injection.
Immunization should be carried out by intramuscular or deep subcutaneous injection. The vaccine should be allowed to reach room temperature before use. Shake before use.
Seroprotection is generally obtained within 2 to 3 weeks. The duration of postvaccinal immunity to homologous strains or to strains closely related to the vaccine strains varies but is usually 6-12 months.
Overdose:Overdosage is unlikely to have any untoward effect.
Undesirable effects:Like all medicines Araflu can have adverse events, although not everybody gets them.
Adverse reactions observed from clinical trials
The following undesirable effects have been observed during clinical trials with the following frequencies: Very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000), including isolated reports.
Nervous system disorders
Common (≥1/100, <1/10):
Skin and subcutaneous tissue disorders
Common (≥1/100, <1/10):
Musculoskeletal and connective tissue disorders
Common (≥1/100, <1/10):
Myalgia (muscular pain), arthralgia (joint pain)*
General disorders and administration site conditions
Common (≥1/100, <1/10):
Fever, malaise (generally feeling unwell), shivering, fatigue.
Local reactions: redness, swelling, pain, ecchymosis (bruising), induration (hardness).*
*These reactions usually disappear within 1-2 days without treatment.
Adverse reactions reported from post-marketing surveillance
Adverse reactions reported from post marketing surveillance are, next to the reactions which have also been observed during the clinical trials, the following:
Blood and lymphatic system disorders:
Transient thrombocytopenia and transient lymphadenopathy
Immune system disorders:
Allergic reactions, in rare cases leading to shock, angioedema.
Nervous system disorders:
Neuralgia, paraesthesiae, febrile convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain-Barre syndrome.
Vasculitis associated in very rare cases with transient renal involvement.
Skin and subcutaneous tissue disorders:
Generalised skin reactions including pruritus, urticaria or nonspecific rash. These undesirable effects are generally transient. When they appear it is advisable to consult a physician. It is important to inform the physician of the appearance of any undesirable effects not described on this leaflet.
Incompatibilities, shelf-life, special precautions for storage, disposal and handling
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Do not use Araflu after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
Araflu must be stored in a refrigerator (2°C - 8°C).
Do not freeze. Keep the syringe in the outer carton in order to protect from light. Any unused product or waste material should be disposed of in accordance with local requirements. Information regarding the medicinal product should always be kept at hand, therefore keep both the box and the package leaflet. Keep out of the reach and sight of children. Shelf life: 1 year.